
Atrion Corporation ATRI
Annual report 2023
added 02-29-2024
Atrion Corporation Accounts Payables 2011-2025 | ATRI
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Atrion Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.63 K | 12.1 K | 7.15 M | 6.64 M | 5.71 M | 5.08 M | 3.93 M | 4.03 M | 3.93 M | 4.53 M | 4.09 M | 3.84 M | 3.64 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.15 M | 6.63 K | 4.04 M |
Quarterly Accounts Payables Atrion Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 199 K | 3.4 M | - | - | - | - | 7.15 M | - | - | - | 6.64 M | - | - | - | 5.71 M | - | - | - | 5.08 M | - | - | - | 3.93 M | - | - | - | 4.03 M | - | - | - | 3.93 M | - | - | - | 4.53 M | - | - | - | 4.09 M | - | - | - | 3.84 M | - | - | - | 3.64 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.15 M | 199 K | 4.32 M |
Accounts Payables of other stocks in the Medical instruments industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
3.57 M | $ 24.56 | 0.7 % | $ 1.13 B | ||
|
Baxter International
BAX
|
968 M | $ 19.52 | 1.93 % | $ 9.96 B | ||
|
Becton, Dickinson and Company
BDX
|
1.97 B | $ 200.48 | -0.23 % | $ 57.7 B | ||
|
Ekso Bionics Holdings
EKSO
|
1.55 M | $ 4.68 | 0.21 % | $ 94.4 M | ||
|
Harvard Bioscience
HBIO
|
5.55 M | $ 0.71 | -4.45 % | $ 30.1 M | ||
|
ICU Medical
ICUI
|
148 M | $ 148.28 | -0.1 % | $ 3.62 B | ||
|
iRhythm Technologies
IRTC
|
7.22 M | $ 170.21 | 0.82 % | $ 5.31 B | ||
|
AtriCure
ATRC
|
25 M | $ 41.07 | -3.09 % | $ 1.93 B | ||
|
electroCore
ECOR
|
2.16 M | $ 4.85 | 2.11 % | $ 26.7 K | ||
|
Repro Med Systems
KRMD
|
975 K | $ 5.8 | 0.35 % | $ 264 M | ||
|
AngioDynamics
ANGO
|
33.3 M | $ 13.42 | 2.13 % | $ 548 M | ||
|
The Cooper Companies
COO
|
300 M | $ 81.36 | -0.88 % | $ 16.2 B | ||
|
LeMaitre Vascular
LMAT
|
1.76 M | $ 83.04 | -1.14 % | $ 1.86 B | ||
|
Glaukos Corporation
GKOS
|
13.4 M | $ 111.73 | 2.6 % | $ 5.41 B | ||
|
Masimo Corporation
MASI
|
253 M | $ 137.35 | -0.72 % | $ 7.32 B | ||
|
Haemonetics Corporation
HAE
|
67 M | $ 80.24 | -3.89 % | $ 4.04 B | ||
|
InfuSystem Holdings
INFU
|
8.34 M | $ 9.22 | -0.27 % | $ 190 M | ||
|
Merit Medical Systems
MMSI
|
68.5 M | $ 86.49 | -0.24 % | $ 5.04 B | ||
|
Intuitive Surgical
ISRG
|
193 M | $ 559.7 | 3.2 % | $ 199 B | ||
|
OraSure Technologies
OSUR
|
8.17 M | $ 2.49 | - | $ 185 M | ||
|
Microbot Medical
MBOT
|
357 K | $ 2.23 | -7.65 % | $ 22.7 M | ||
|
Milestone Scientific
MLSS
|
780 K | $ 0.36 | -7.4 % | $ 28.7 M | ||
|
Nephros
NEPH
|
873 K | $ 4.98 | -0.8 % | $ 51.7 M | ||
|
NeuroMetrix
NURO
|
363 K | - | 5.05 % | $ 9.02 M | ||
|
ResMed
RMD
|
159 M | $ 251.67 | -0.27 % | $ 36.8 B | ||
|
Envista Holdings Corporation
NVST
|
175 M | $ 22.07 | 0.46 % | $ 3.8 B | ||
|
Pro-Dex
PDEX
|
4.61 M | $ 44.0 | 1.43 % | $ 145 M | ||
|
STAAR Surgical Company
STAA
|
16.7 M | $ 23.49 | -2.65 % | $ 1.15 B | ||
|
STERIS plc
STE
|
281 M | $ 253.98 | 0.82 % | $ 25 B | ||
|
Stereotaxis
STXS
|
3.19 M | $ 2.35 | -1.05 % | $ 190 M | ||
|
Pulse Biosciences
PLSE
|
1.84 M | $ 14.04 | -1.4 % | $ 674 M | ||
|
Predictive Oncology
POAI
|
1.14 M | - | - | $ 32.4 M | ||
|
Repligen Corporation
RGEN
|
19.6 M | $ 160.09 | 1.72 % | $ 8.92 M | ||
|
Utah Medical Products
UTMD
|
769 K | $ 57.54 | -0.96 % | $ 209 M | ||
|
DENTSPLY SIRONA
XRAY
|
241 M | $ 11.43 | -1.21 % | $ 2.32 B | ||
|
Retractable Technologies
RVP
|
4.29 M | $ 0.84 | 1.99 % | $ 25.1 M | ||
|
Teleflex Incorporated
TFX
|
141 M | $ 126.88 | 0.17 % | $ 5.94 B | ||
|
West Pharmaceutical Services
WST
|
239 M | $ 271.82 | 1.6 % | $ 19.8 B |